Clinical Trials Logo
  1. Home
  2. Metastatic
  3. NCT02069730

A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes

Salivary Gland Cancer Clinical Trial

Official title:
Genomic Profiling and Matched Therapy for Recurrent or Metastatic Salivary Gland Neoplasms

Clinical Trial Summary

This is a study of select drug therapies in patients with salivary gland cancer. The study has two phases: a molecular profiling phase (phase 1) and a treatment phase (phase 2). Based on the Molecular profiling results in phase the participants will receive matched treatment if a specific aberration is identified or will receive treatment with Selinexor if unmatched and no druggable aberration is identified.

Clinical Trial Description

In molecular profiling phase of the study, participants will provide a sample of their tumor tissue to test for changes in certain genes that show whether certain drug treatments will be more useful than others. Once participants have undergone molecular profiling, they will be offered a drug treatment depending on the results. Certain drug treatments are designed to target certain gene changes. If there is a matching drug treatment, participants will be offered that treatment (either outside a clinical trial or within a clinical trial). If there are no gene changes or there are changes to genes were there are no drug treatments available for those certain changes, participants will be offered the study drug, Selinexor. Cancer is the uncontrolled growth of cells. Research shows that one way cancer cells can grow uncontrollably is when certain proteins, called exporter proteins, are present in high levels in the body. These proteins prevent certain other proteins important in protecting cells from becoming cancerous and important in the controlling the growth of cells, from working. The study drug Selinexor is new class of drug called Selective Inhibitor of Nuclear Export (SINE) that blocks the exporter proteins from working which may allow the other proteins to work and slow or stop tumors from growing. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02069730
Study type Interventional
Source University Health Network, Toronto
Contact
Status Active, not recruiting
Phase N/A
Start date June 2014
Completion date December 2027
View Details
See also
  Status Clinical Trial Phase
Terminated NCT03729297 - Cabozantinib in Advanced Salivary Gland Cancer Patients Phase 2
Active, not recruiting NCT01969578 - Androgen Deprivation Therapy in Advanced Salivary Gland Cancer Phase 2
Completed NCT01703455 - Activity of Sorafenib in Salivary Gland Cancer Phase 2
Recruiting NCT04140526 - Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC Phase 1/Phase 2
Active, not recruiting NCT05010629 - 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma Phase 2
Active, not recruiting NCT03781986 - APG-115 in Salivary Gland Cancer Trial Phase 1/Phase 2
Completed NCT03319641 - PSMA-PET Imaging for Advanced ACC/SDC N/A
Recruiting NCT02012699 - Integrated Cancer Repository for Cancer Research
Recruiting NCT04028479 - The Registry of Oncology Outcomes Associated With Testing and Treatment
Recruiting NCT05483374 - The Head and Neck Registry of the European Reference Network on Rare Adult Solid Cancers
Completed NCT04291300 - Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients Phase 2
Active, not recruiting NCT03172624 - Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer Phase 2
Completed NCT00509002 - Iressa Study in Patients With Salivary Gland Cancer Phase 2
Active, not recruiting NCT05008237 - Weekly Docetaxel Plus Cisplatin as First-line Chemotherapy in Metastatic Salivary Gland Cancer Patients : a Multicenter Phase II Study Phase 2
Recruiting NCT03360890 - Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors Phase 2
Not yet recruiting NCT05898373 - Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC Phase 1/Phase 2
Recruiting NCT04209660 - Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers Phase 2
Completed NCT01344356 - Stereotactic Body Radiotherapy for Head and Neck Tumors Phase 4
Completed NCT03602079 - Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene Phase 1/Phase 2
Not yet recruiting NCT06091878 - Gene Expression Profiling in a Validation Cohort of Locally Advanced and Recurrent/Metastatic Salivary Gland Cancers